Ainos, Inc. (NASDAQ:AIMD) Sees Large Decline in Short Interest

Ainos, Inc. (NASDAQ:AIMD) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 237,400 shares, a drop of 49.4% from the February 13th total of 469,400 shares. Based on an average daily trading volume, of 630,500 shares, the days-to-cover ratio is currently 0.4 days. Currently, 4.9% of the shares of the company are sold short.

Ainos Stock Up 8.6 %

Shares of NASDAQ AIMD opened at $0.52 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.37 and a quick ratio of 1.33. The stock has a market capitalization of $8.04 million, a PE ratio of -0.32 and a beta of 1.51. Ainos has a one year low of $0.40 and a one year high of $1.50. The business’s fifty day moving average price is $0.62 and its 200-day moving average price is $0.54.

Ainos (NASDAQ:AIMD) last released its quarterly earnings data on Friday, March 7th. The company reported ($0.26) EPS for the quarter.

About Ainos

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.